Coccidioidomycosis After Renal Transplantation in an Endemic Area

Coccidioidomycosis is an endemic fungal infection of the desert southwestern United States of particular concern for immunosuppressed renal transplant recipients. The clinical course of coccidioidomycosis can be severe in immunosuppressed patients, with high rates of dissemination and mortality, and antifungal prophylaxis is routinely administered to high-risk patients. We sought to determine the impact of coccidioidomycosis on patients who received their renal transplant at our hospital in Phoenix, Arizona. A retrospective records review of the first 205 patients who received a renal transplant between June 1999 and December 2003 identified 6 patients (3%) who had contracted coccidioidomycosis after transplantation. All six cases occurred more than 6 months after transplantation. Two of these six patients had disseminated coccidioidomycosis. Two patients, one with pulmonary infection and one with disseminated infection, died. None of the six patients with coccidioidomycosis after transplantation had identified risk factors before transplantation. No high-risk patient who received targeted antifungal prophylaxis had a reactivation of coccidioidomycosis after transplantation. Treatment for acute rejection and induction with antithymocyte globulin did not appear to increase the risk of subsequent coccidioidomycosis.     

肾移植术患者连续腰麻的效果

目的评价肾移植术患者连续腰麻（CSA）的效果。方法择期肾移植术患者24例，ASAⅢ级，随机分为3组（n=8），DCEA组：L1-2与L3-4间隙硬膜外穿刺，注入2％利多卡因试验剂量5ml，初始剂量10—20ml（0．75％布比卡因＋2％利多卡因，1：1混合液）；CSEA组：L1-2间隙硬膜外穿刺，L3.4间隙经硬膜外针行腰麻穿刺，注入重比重0.5％布比卡因10～13mg，调节体位和硬膜外给药量（0．75％布比卡因＋2％利多卡因，1：1混合液）；CSA组：L3.4间隙经硬膜外针行腰麻穿刺，注入重比重0．5％布比卡因10～13mg，根据阻滞平面给药2—4mg，次。3组目标阻滞平面k，记录入手术室后（基础值）和首剂量局麻药注入后1、5、10、15minSP、DP、MAP、HR。于麻醉前（T1）、移植肾植入髂窝后即刻（T2）、手术结束（T3）测血糖；记录开始注入局麻药至出现满意阻滞平面的时间、肌松程度、肾脏植入髂窝后患者不适感和局麻药总量。结果与CSEA组比较，阻滞平面达T6时间DCEA组延长（P〈0．05），局麻药总量DCEA组增多，CSA组减少（P〈0．05）。3组血糖比较差异无统计学意义（P〉0．05）。镇痛效应及肌松程度CSA组优于DCEA组和CSEA组。结论与硬膜外阻滞和脊椎．硬膜外联合阻滞相比，肾移植术患者连续腰麻产生较好的镇痛、肌松效果，且局麻药用量较少。     

一种双侧供肾大鼠肾移植模型的建立

目的 探讨同时取大鼠双侧肾脏分别移植的可行性，其目的是节省实验费用、缩短手术时间。方法 以近交系Brown-Norway大鼠为供者，同时取其双肾作为供肾，原位灌洗；近交系Lewis大鼠为受者，切除其左肾，移植供肾1只。以冠状动脉造影支架为支撑行供肾静脉与受者肾静脉端端吻合，供肾动脉与受者的腹主动脉行端侧吻合，供肾输尿管膀胱瓣与受者的膀胱吻合。受者术中预置右侧肾脏血管体外结扎线，术后3d结扎。结果 每只供鼠手术耗时约40min，热缺血时间约10S，冷缺血时间约20min。40次实验均获成功，移植肾功能正常，在不用免疫抑制剂的情况下，受者存活时间均超过7d。结论 同时取双侧肾脏分别移植给2个受者是可行的，可降低实验成本；要获得相同数量的供肾，同时取双肾的耗时较仅取单侧肾脏大大缩短。     

转染人VEGF165基因对大鼠胰岛移植物再血管化及生物学功能的影响

目的探讨转染人血管内皮生长因子（VEGF）基因对大鼠胰岛移植物再血管化和生物学功能的影响。方法实验分二步进行，首先构建携带人血管内皮生长因子165（hVEGF165）基因的重组腺病毒载体AdhVEGF165，用其按病毒／细胞的感染倍数（MOI）分别为10、100、500的比例在体外转染新鲜分离、纯化的近交系Lewis大鼠胰岛，检测体外培养的胰岛表达hVEGF165基因的情况；然后按MOI为10的比例在体外用AdhVEGF165转染Lweis大鼠胰岛，再经门静脉注射至近交系Lewis大鼠的肝脏内（VEGF组），并设不含hVEGF165基因的空载体转染对照组（GFP组）和磷酸盐缓冲液处理对照组（PBS液组），术后测定受鼠的血糖变化，进行静脉糖耐量试验（IVGTT），并观察受鼠肝脏中移植胰岛的组织学变化。结果体外转染hVEGF165基因的大鼠胰岛分泌至细胞外的hVEGF165的浓度显著高于未转染者（P〈0．01）。糖尿病大鼠移植转染hVEGF165基因的胰岛后，静脉注射葡萄糖后40、60、120min时的血糖水平显著低于GFP组和PBS液组（P〈0．05）；40min时体循环中胰岛素的浓度，VEGF组显著高于GFP组和PBS液组（P〈0．05）；VEGF组移植胰岛内CD34和胰岛素免疫组化染色的强度均高于GFP组和PBS液组。结论转染hVEGF165基因对胰岛移植物的再血管化和生物学功能有促进作用。     

肾移植术后并发尿路上皮肿瘤的临床分析

目的 分析肾移植患者并发尿路上皮肿瘤的特点，探讨其诊治方法。方法 自1998～2003年肾移植患者1293例，术后发生尿路上皮恶性肿瘤21例（1．6％）。男4例，女17例。17例原发病为慢性问质性肾炎。发生尿路上皮肿瘤距肾移植6～62个月，平均26个月。其中膀胱癌6例，单侧肾盂或输尿管癌6例，单侧肾盂或输尿管、膀胱癌8例，双侧肾盂输尿管癌1例。10例上尿路肿瘤发生部位与移植肾同侧，4例发生于移植肾对侧。临床症状以无痛性肉服血尿和反复泌尿系感染为主。19例行手术治疗，术后所有患者免疫抑制剂用量减少1／3并辅以局部灌注化疗。结果 2例行姑息性治疗的晚期肿瘤患者分别于发现肿瘤5、8个月死亡。余19例现已随访2～5年。13例肿瘤复发，复发部位为膀胱或对侧原。肾、输尿管。所有患者在免疫抑制剂减量期间均未出现急性排斥。2例因切除移植肾恢复透析，17例肾功能正常。结论 慢性间质性。肾炎导致。肾功能衰竭的。肾移植患者和女性肾移植患者易发生移植后尿路上皮肿瘤；移植肾同侧上尿路较对侧好发肿瘤；对移植肾对侧为首发的上尿路发生肿瘤者可预防性行双侧上尿路根治性切除。     

肝移植术后巨细胞病毒性肺炎的临床特点和治疗方法

目的 探讨肝移植术后巨细胞病毒（CMV）性肺炎的临床特点和治疗方法。方法 回顾性分析2003年10月至2005年6月间施行肝移植的451例患者的临床资料，对肝移植术后CMV性肺炎的临床特点和治疗方法进行总结。结果 在451例患者中，发生CMV性肺炎7例，感染率为1．66％。CMV性肺炎的症状明显早于体征，7例患者均无明显诱因出现高热，约1周后逐渐出现干咳、气促、呼吸困难等；血氧饱和度降低，血气分析提示低氧血症；CMV pp65抗原检测均为阳性。CMV性肺炎患者采用更昔洛韦联合膦甲酸钠抗病毒治疗，同时采取停用免疫抑制剂、加用较大剂量的丙种球蛋白和适量的胸腺肽等的个体化免疫调节方案以及广谱抗生素等综合治疗方法，6例治愈，治愈率为85．7％。结论 CMV性肺炎的早期临床表现虽然缺乏特异性，但仍有规律可循，CMV pp65抗原检测法具有特异性和敏感性高的特点。采取联合抗病毒和个体化免疫调节等综合措施治疗CMV性肺炎效果确切。     

单钉-棒固定在胸腰椎结核前路手术中的应用

目的探讨脊柱结核手术内固定的有效方式。方法2002年6月~2004年6月,在手术前有效抗结核化疗的基础上,采用前路病灶清除、植骨融合及单钉-棒内固定的手术方式治疗胸、腰椎结核患者54例。术中在保证彻底清创的基础上注意保留病椎有血供的部分和无明显破坏的椎间盘,以减少切除范围和融合的节段,有神经症状者注意行椎管前侧减压。骨缺损采用自体髂骨、异体髂骨 自体碎骨、或钛网 自体碎骨的方法修复,安置单钉-棒时注意对移植骨块适当加压。患者术后卧床10d左右,然后在支具的保护下下床活动。本组共有41例患者获得随访,手术后随访的时间7~31个月,平均18个月。结果患者所有的结核病灶均顺利愈合,植骨稳定,无明显移位和塌陷,内固定器无松脱和折断,其中37例达到骨性愈合标准;脊柱后凸角平均矫正达23°,患者术前伴有的神经症状也大部分消失,绝大部分患者恢复日常生活、工作。结论前路单钉-棒内固定不仅能够维持胸、腰椎结核手术后脊柱的稳定,防止移植骨块的脱位、塌陷和骨不愈合的发生,而且可以最大范围地减少融合节段,减少术中创伤,故是手术治疗胸、腰椎结核的可靠固定方式。     

Emerging Issues in Hepatitis C Virus-Positive Liver and Kidney Transplant Recipients

Hepatitis C virus (HCV) infection is a major health care issue in liver and kidney transplantation. Besides negatively affecting both patient and graft survival, HCV is associated with a heightened risk for new onset diabetes mellitus (NODM). The mechanisms underlying the diabetogenicity of HCV are complex but are likely to involve insulin resistance caused by inhibitory actions of the virus on insulin regulatory pathways in the liver. The resultant glucose dysregulation is an important determinant of increased morbidity and mortality in liver and kidney recipients. This review highlights the concerns for outcomes in HCV-positive liver and kidney transplant patients with particular focus on the interrelationship between hepatitis C and diabetes. Data about the potential role of calcineurin inhibitors, corticosteroids and mycophenolate mofetil in HCV infection and HCV-associated NODM will also be discussed.     

Preservation of Bile Ductules Mitigates Bile Duct Loss

The finer branches of the biliary tree (FBBT) contain a regenerative compartment. We hypothesized that preservation of the FBBT together with its microvasculature will lead to recovery of biliary damage and prolonged preservation of bile ductules during the development of chronic liver allograft rejection. The interlobular bile ducts, portal bile ductules and extraportal biliary cells with and without microvessels were studied in sequential biopsies in five patients who fulfilled the Banff criteria of early chronic rejection (CR) (imminence group). Biopsies of CR patients (n = 12) served as controls. Biopsies were double immunostained with CD34 (microvessels) and cytokeratin 7 (biliary structures). Proliferation and proangiogenic activity were assessed with Ki67 and VEGF-A immunostaining. Severe damage of bile ducts in the imminence group did not progress to significant bile duct loss. This was associated with a high proliferative activity in all biliary structures and preservation of the microvascular compartment. VEGF-A expression was increased in all but the reperfusion biopsies. In conclusion, both regenerative activity of the FBBT and an intact microvascular compartment are associated with less damage of the biliary tree and could therefore be prerequisites for biliary regeneration.     

Tacrolimus Combined with Two Different Dosages of Sirolimus in Kidney Transplantation: Results of a Multicenter Study

Tacrolimus combined with mycophenolate mofetil (MMF) is an effective regimen in kidney transplantation. This study compared the efficacy of combining tacrolimus and two different dosages of sirolimus with an established tacrolimus-MMF regimen. Each day in addition to tacrolimus, 325 patients received 2 mg sirolimus (TAC-SRL2 mg), 325 patients received 0.5 mg sirolimus (TAC-SRL0.5 mg) and 327 patients 1 g MMF (TAC-MMF). The initial tacrolimus dose was 0.2 mg/kg/day. Sirolimus patients received loading doses of 6 or 1.5 mg, and daily doses of 2 or 0.5 mg thereafter. Steroid administration was identical for all groups. The incidence of biopsy-proven acute rejection was lower in the TAC-SRL2 mg group (15.7%) compared with the TAC-SRL0.5 mg (25.2%, p = 0.003) and the TAC-MMF groups (22.3%, p = 0.036). Six-month graft survival was 91.0% (TAC-SRL2 mg), 92.6% (TAC-SRL0.5 mg) and 92.4% (TAC-MMF); the respective values for patient survival were 98.1%, 97.8% and 97.9%. Thirty-four patients (10.5%), 19 patients (5.8%) and 16 patients (4.9%) in the TAC-SRL2 mg, TAC-SRL0.5 mg and TAC-MMF groups, respectively, discontinued the study because of adverse events. Hyperlipemia was reported more often in the TAC-SRL2 mg group (24.0%) compared with 19.4% (TAC-SRL0.5 mg) and 11.0% (TAC-MMF; p < 0.05). Combining 2 mg sirolimus/day with tacrolimus results in lower rates of acute rejection, but a higher incidence of adverse events.